CA2592605A1 - Method for stabilizing anti-dementia drug - Google Patents
Method for stabilizing anti-dementia drug Download PDFInfo
- Publication number
- CA2592605A1 CA2592605A1 CA002592605A CA2592605A CA2592605A1 CA 2592605 A1 CA2592605 A1 CA 2592605A1 CA 002592605 A CA002592605 A CA 002592605A CA 2592605 A CA2592605 A CA 2592605A CA 2592605 A1 CA2592605 A1 CA 2592605A1
- Authority
- CA
- Canada
- Prior art keywords
- molecular weight
- high molecular
- dementia drug
- substance
- acidic substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
The present invention provides a method for stabilizing an anti-dementia drug in a pharmaceutical composition containing the anti-dementia drug and a high molecular weight basic substance by adding a high molecular weight acidic substance to said pharmaceutical composition. Further, the present invention provides a pharmaceutical composition containing an anti-dementia drug and a high molecular basic substance in which a high molecular weight acidic substance is contained for stabilizing the anti-dementia drug. Furthermore, the present invention provides a method for manufacturing a pharmaceutical composition which comprises steps wherein a solution or suspension containing a high molecular weight acidic substance is added to a mixture of an anti-dementia drug and a high molecular weight basic substance for the sake of stabilizing the anti-dementia drug.
Claims (31)
1. A method for stabilizing an anti-dementia drug, comprising adding a high molecular weight acidic substance into a pharmaceutical composition comprising the anti-dementia drug and a high molecular weight basic substance.
2. The method according to Claim 1, wherein the high molecular weight acidic substance is added in an amount that degradation product of the anti-dementia drug which are produced by contact between the anti-dementia drug and the high molecular weight basic substance can be suppressed.
3. The method according to Claim 1 or 2, wherein the anti-dementia drug is a compound having a tertiary amino group.
4. The method according to any one of Claims 1 to 3, wherein the anti-dementia drug is selected from the group consisting of rivastigmine, galantamine, donepezil, 3-[1-(phenylmethyl)piperidin-4-yl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propane and 5,7-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one and pharmaceutically acceptable salts thereof.
5. The method according to any one of Claims 1 to 4, wherein the anti-dementia drug is donepezil or a pharmaceutically acceptable salt thereof.
6. The method according to any one of Claims 1 to 5, wherein the high molecular weight basic substance is a water-insoluble polymer substance.
7. The method according to any one of Claims 1 to 6, wherein the high molecular weight basic substance is at least one selected from the group consisting of ethylcellulose, ethyl acrylate-methyl methacrylate copolymer and polyethylene oxide.
8. The method according to any one of Claims 1 to 7, wherein the high molecular weight acidic substance is an enteric polymer substance.
9. The method according to any one of Claims 1 to 8, wherein the high molecular weight acidic substance is at least one selected from the group consisting of methacrylic acid-ethyl acrylate copolymer, methacrylic acid-methyl methacrylate copolymer, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate.
10. The method according to any one of Claims 1 to 9, further comprising adding at least one of a low molecular weight acidic substance and an anti-oxidant.
11. The method according to Claim 10, wherein the low molecular weight acidic substance is at least one selected from the group consisting of carboxylic acids, sulfonic acids, hydroxy acids, acidic amino acids and inorganic acids.
12. The method according to Claim 10 or 11, wherein the low molecular weight acidic substance is at least one selected from the group consisting of hydroxy acids, acidic amino acids and inorganic acids.
13. The method according to any one of Claims 10 to 12, wherein the low molecular weight acidic substance is at least one selected from the group consisting of succinic acid, tartaric acid, citric acid, fumaric acid, maleic acid, malic acid, aspartic acid, glutamic acid, glutamic acid hydrochloride, hydrochloric acid and phosphoric acid.
14. The method according to any one of Claims 10 to 13, wherein the low molecular weight acidic substance is at least one selected from the group consisting of succinic acid, tartaric acid, citric acid, malic acid, aspartic acid, glutamic acid, glutamic acid hydrochloride, hydrochloric acid and phosphoric acid.
15. The method according to any one of Claims 10 to 14, wherein the anti-oxidant is at least one selected from the group consisting of ascorbic acids, sulfur-containing amino acids, hydroquinone derivatives and tocopherols.
16. A use of a high molecular weight acidic substance for suppressing degradation product of an anti-dementia drug produced by contact between the anti-dementia drug and a high molecular weight basic substance.
17. A use of a high molecular weight acidic substance and at least one of a low molecular weight acidic substance and an anti-oxidant for suppressing degradation product of an anti-dementia drug produced by contact between the anti-dementia drug and a high molecular weight basic substance.
18. A pharmaceutical composition comprising an anti-dementia drug and a high molecular weight basic substance, wherein the composition further comprises a high molecular weight acidic substance for stabilizing the anti-dementia drug.
19. The pharmaceutical composition according to Claim 18, further comprising at least one of a low molecular weight acidic substance and an anti-oxidant for stabilizing the anti-dementia drug.
20. The pharmaceutical composition according to Claim 18, wherein the composition comprises a matrix comprising a mixture of the anti-dementia drug, the high molecular weight basic substance and the high molecular weight acidic substance for stabilizing the anti-dementia drug.
21. The pharmaceutical composition according to Claim 20, wherein at least one of a low molecular weight acidic substance and an anti-oxidant for stabilizing the anti-dementia drug is mixed into the matrix.
22. The pharmaceutical composition according to Claim 18, wherein the pharmaceutical composition comprises a core comprising the anti-dementia drug and a coating layer comprising the high molecular weight basic substance which covers the core, and wherein the high molecular weight acidic substance is mixed into at least one of the core and the coating layer.
23. The pharmaceutical composition according to Claim 22, wherein at least one of a low molecular weight acidic substance and an anti-oxidant for stabilizing the anti-dementia drug is further mixed into at least one of the core and the coating layer.
24. The pharmaceutical composition according to any one of Claims 18 to 23, wherein the pharmaceutical composition is a sustained-release preparation.
25. The pharmaceutical composition according to any one of Claims 18 to 24, wherein the high molecular weight acidic substance is an enteric polymer substance.
26. A matrix type sustained-release preparation comprising:
donepezil or a pharmaceutically acceptable salt thereof;
a high molecular weight basic substance; and a high molecular weight acidic substance.
donepezil or a pharmaceutically acceptable salt thereof;
a high molecular weight basic substance; and a high molecular weight acidic substance.
27. The matrix type sustained-release preparation according to claim 26, further comprising at least one of a low molecular weight acidic substance and an anti-oxidant.
28. A method for manufacturing a pharmaceutical composition, comprising the steps of:
mixing an anti-dementia drug and a high molecular weight basic substance;
and granulating the mixture, wherein a high molecular weight acidic substance for stabilizing the anti-dementia drug is added to the mixture of the anti-dementia drug and the high molecular weight basic substance during at least one of the mixing step and the granulating step.
mixing an anti-dementia drug and a high molecular weight basic substance;
and granulating the mixture, wherein a high molecular weight acidic substance for stabilizing the anti-dementia drug is added to the mixture of the anti-dementia drug and the high molecular weight basic substance during at least one of the mixing step and the granulating step.
29. The method according to Claim 28, wherein the high molecular weight acidic substance is added as a powder.
30. The method according to claim 28 or 29, wherein at least one of a low molecular weight acidic substance and an anti-oxidant for stabilizing the anti-dementia drug is further added to the mixture of the anti-dementia drug and the high molecular weight basic substance during at least one of the mixing step and the granulating step.
31. The method according to Claim 29, wherein at least one of the low molecular weight acidic substance and the anti-oxidant is added as a solution or suspension.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004376770 | 2004-12-27 | ||
JP2004-376770 | 2004-12-27 | ||
JP2005041492 | 2005-02-18 | ||
JP2005-041492 | 2005-02-18 | ||
PCT/JP2005/024254 WO2006070930A1 (en) | 2004-12-27 | 2005-12-27 | Method for stabilizing anti-dementia drug |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2592605A1 true CA2592605A1 (en) | 2006-07-06 |
CA2592605C CA2592605C (en) | 2010-12-07 |
Family
ID=36615033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2592605A Expired - Fee Related CA2592605C (en) | 2004-12-27 | 2005-12-27 | Method for stabilizing anti-dementia drug |
Country Status (14)
Country | Link |
---|---|
US (2) | US8481565B2 (en) |
EP (1) | EP1830886B1 (en) |
JP (2) | JP2008525313A (en) |
KR (1) | KR100866720B1 (en) |
AU (1) | AU2005320547B2 (en) |
BR (1) | BRPI0518396A2 (en) |
CA (1) | CA2592605C (en) |
HK (1) | HK1112399A1 (en) |
IL (1) | IL183650A (en) |
MX (1) | MX2007007836A (en) |
NO (1) | NO20073482L (en) |
NZ (1) | NZ555693A (en) |
RU (1) | RU2401125C2 (en) |
WO (1) | WO2006070930A1 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
MX2007007836A (en) | 2004-12-27 | 2007-08-20 | Eisai R&D Man Co Ltd | Method for stabilizing anti-dementia drug. |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
US20090023778A1 (en) * | 2005-04-28 | 2009-01-22 | Eisai R&D Management Co., Ltd. | Composition Containing Anti-Dementia Drug |
WO2008066183A1 (en) * | 2006-12-01 | 2008-06-05 | Nitto Denko Corporation | Skin adhesive preparation comprising stabilized donepezil |
KR20090086565A (en) * | 2006-12-01 | 2009-08-13 | 닛토덴코 가부시키가이샤 | Skin adhesive preparation comprising stabilized donepezil |
JP5037523B2 (en) * | 2006-12-01 | 2012-09-26 | 日東電工株式会社 | Method for suppressing coloration of donepezil-containing patch preparation, and method for reducing the amount of donepezil related substances produced |
CN101605545B (en) * | 2006-12-01 | 2011-10-05 | 日东电工株式会社 | Skin adhesive preparation comprising stabilized donepezil |
EP2127651A4 (en) * | 2007-01-19 | 2012-08-01 | Eisai R&D Man Co Ltd | Stabilized medicinal composition containing donepezil, method of producing the same and method for stabilization |
GR20070100405A (en) * | 2007-06-26 | 2009-01-20 | Genepharm �.�. | Improved pharmaceutical composition containing acetylcholine esterace inhibitor and method for the preparation thereof |
ES2634421T3 (en) | 2008-03-27 | 2017-09-27 | Chase Pharmaceuticals Corporation | Use and composition to treat dementia |
DE102009041839A1 (en) * | 2009-09-18 | 2011-03-24 | Dolorgiet Gmbh & Co. Kg | Preparation of a donepezil-containing tablet, useful for treating mild to moderate dementia of the Alzheimer type, comprises wet granulation of donepezil with granulating liquid and excipients e.g. cellulose and starch |
US8962014B2 (en) * | 2009-12-22 | 2015-02-24 | Acino Ag | Transdermal therapeutic system for administering rivastigmine or derivatives thereof |
US10076502B2 (en) | 2009-12-22 | 2018-09-18 | Luye Pharma Ag | Transdermal therapeutic system for administering rivastigmine or derivatives thereof |
US20120294947A1 (en) * | 2009-12-28 | 2012-11-22 | Nipro Corporation | Oral Preparation Having Improved Quality |
US20110218216A1 (en) * | 2010-01-29 | 2011-09-08 | Kumaravel Vivek | Extended release pharmaceutical composition of donepezil |
JP5749247B2 (en) * | 2010-02-22 | 2015-07-15 | 第一三共株式会社 | Oral sustained-release solid preparation |
EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
JP2011213606A (en) * | 2010-03-31 | 2011-10-27 | Sawai Pharmaceutical Co Ltd | Method for producing solid preparation containing donepezil |
US20140004189A1 (en) * | 2011-01-25 | 2014-01-02 | Cadila Healthcare Limited | Modified release pharmaceutical compositions memantine |
JP5656258B2 (en) * | 2011-03-09 | 2015-01-21 | 塩野義製薬株式会社 | Orally disintegrating tablets containing galantamine |
EP2502620A1 (en) | 2011-03-24 | 2012-09-26 | Krka Tovarna Zdravil, D.D., Novo Mesto | Solid pharmaceutical composition comprising donepezil |
CN103417490B (en) * | 2012-05-21 | 2015-06-17 | 成都康弘药业集团股份有限公司 | Granule containing donepezil and preparation method thereof |
BR112015020773A2 (en) * | 2013-02-28 | 2017-07-18 | Lupin Ltd | timed release pharmaceutical composition |
KR102241113B1 (en) | 2013-02-28 | 2021-04-15 | 루핀 리미티드 | Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters |
KR101990951B1 (en) * | 2015-04-27 | 2019-06-20 | 주식회사 네비팜 | A sustained releasing Pharmaceutical Composition comprising Rivastigmine |
KR101938872B1 (en) * | 2016-09-30 | 2019-01-16 | 주식회사 바이오파마티스 | Composition comprising complex for prevention and treatment of dementia and cognitive impairment |
CN110662534A (en) | 2017-05-31 | 2020-01-07 | 勃林格殷格翰国际有限公司 | Pharmaceutical compositions and dosage forms comprising (E) -4- (2- (aminomethyl) -3-fluoroallyloxy) -N-tert-butylbenzamide, processes for their preparation, methods of treatment and uses thereof |
KR102115102B1 (en) | 2018-12-21 | 2020-05-26 | 동아에스티 주식회사 | Percutaneous Absorption Preparation Comprising Stabilized Donepezil |
Family Cites Families (227)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1894239A (en) * | 1930-01-20 | 1933-01-10 | Ig Farbenindustrie Ag | Production of molybdenum and tungsten carbonyls |
US2327996A (en) | 1941-11-24 | 1943-08-31 | Thompson W Burnam | Process of dehydrating mineral oil emulsions |
HU187215B (en) * | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
IL72381A (en) * | 1983-07-20 | 1988-03-31 | Sanofi Sa | Pharmaceutical composition based on valproic acid |
SE452177B (en) | 1983-09-30 | 1987-11-16 | Nils Anders Lennart Wikdahl | DEVICE FOR FRACTIONING FIBER SUSPENSIONS |
SE457505B (en) | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | LAMINATED ORAL PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR ITS PREPARATION |
DK62184D0 (en) | 1984-02-10 | 1984-02-10 | Benzon As Alfred | DIFFUSION COATED POLYDEPOT PREPARATION |
US4772475A (en) | 1985-03-08 | 1988-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Controlled-release multiple units pharmaceutical formulation |
NL8500724A (en) | 1985-03-13 | 1986-10-01 | Univ Groningen | DEVICES FOR REGULAR RELEASE OF ACTIVE SUBSTANCES AND METHOD OF MANUFACTURE THEREOF |
US4892742A (en) * | 1985-11-18 | 1990-01-09 | Hoffmann-La Roche Inc. | Controlled release compositions with zero order release |
IL81419A0 (en) | 1986-01-30 | 1987-08-31 | Syntex Inc | Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation |
US4940556A (en) * | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
IE63321B1 (en) | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
NL8701335A (en) * | 1986-06-21 | 1988-01-18 | Sandoz Ag | ORAL PHARMACEUTICAL PREPARATIONS. |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4710384A (en) | 1986-07-28 | 1987-12-01 | Avner Rotman | Sustained release tablets made from microcapsules |
CA1308357C (en) * | 1987-01-28 | 1992-10-06 | Tohru Chiba | Method for the preparation of a coated solid medicament |
US4851232A (en) * | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
US4968508A (en) | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US4894239A (en) * | 1987-06-02 | 1990-01-16 | Takeda Chemical Industries, Ltd. | Sustained-release preparation and production thereof |
EP0297866A3 (en) | 1987-07-01 | 1989-12-13 | The Boots Company PLC | Therapeutic agents |
US4792452A (en) | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4891223A (en) * | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
JP2643222B2 (en) * | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | Multi-layer granules |
US5254347A (en) | 1988-03-31 | 1993-10-19 | Tanabe Seiyaku Co., Ltd. | Controlled release pharmaceutical preparation and method for producing the same |
JPH0768125B2 (en) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | Oral formulation of acid labile compounds |
DE3818207A1 (en) | 1988-05-28 | 1989-11-30 | Bosch Gmbh Robert | TIRE PRESSURE AND TEMPERATURE SENSOR |
DE3827214A1 (en) * | 1988-08-11 | 1990-02-15 | Roehm Gmbh | RETARDED MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF |
JP2514078B2 (en) * | 1988-08-22 | 1996-07-10 | エスエス製薬株式会社 | Compressed formulation |
JP2893191B2 (en) * | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | Controlled release matrix agent |
AU645003B2 (en) | 1988-11-08 | 1994-01-06 | Takeda Chemical Industries Ltd. | Sustained release preparations |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5278474A (en) * | 1989-01-12 | 1994-01-11 | Tokyo Densoku Kabushiki Kaisha | Discharge tube |
ES2077023T3 (en) | 1989-03-10 | 1995-11-16 | Yamanouchi Pharma Co Ltd | COATING MATERIAL THAT CONTROLS THE RELEASE OF A MEDICINAL PRODUCT FOR FORMULATIONS OF PROLONGED ACTIVITY. |
NZ233403A (en) * | 1989-04-28 | 1992-09-25 | Mcneil Ppc Inc | Simulated capsule-like medicament |
JP2572673B2 (en) | 1990-07-25 | 1997-01-16 | エスエス製薬株式会社 | Sustained-release tablets |
US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
HU9203780D0 (en) | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
DE4225730C2 (en) * | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Process for the preparation of solid dosage forms with protracted 2-stage release |
IT1258143B (en) | 1992-09-11 | 1996-02-20 | Alfa Wassermann Spa | PROGRAMMED SALE TABS CONTAINING NAPROXEN |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
KR950007873A (en) * | 1993-09-20 | 1995-04-15 | 후꾸하라 요시하루 | Biologics Sustained-Release Pharmaceutical Formulations |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
JP3071467B2 (en) | 1993-12-29 | 2000-07-31 | メルク シヤープ エンド ドーム リミテツド | Substituted morpholine derivatives and their use as therapeutic agents |
AT403988B (en) | 1994-05-18 | 1998-07-27 | Lannacher Heilmittel | SOLID ORAL RETARDED PREPARATION |
US5698224A (en) * | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
JPH0826977A (en) * | 1994-07-19 | 1996-01-30 | Tanabe Seiyaku Co Ltd | Elution-controlled type oral preparation |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US20020006438A1 (en) | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
US5871776A (en) * | 1995-01-31 | 1999-02-16 | Mehta; Atul M. | Controlled-release nifedipine |
US6083532A (en) * | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
FI98343C (en) | 1995-03-21 | 1997-06-10 | Orion Yhtymae Oy | Oral formulation |
AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
IT1282650B1 (en) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
JPH09323926A (en) * | 1996-03-15 | 1997-12-16 | Nikken Chem Co Ltd | Sustained release tablet of sodium valproate |
US6156340A (en) | 1996-03-29 | 2000-12-05 | Duquesne University Of The Holy Ghost | Orally administrable time release drug containing products |
US6096339A (en) | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
JP2000511161A (en) * | 1996-05-24 | 2000-08-29 | アンジオテック ファーマシュウティカルズ,インコーポレイテッド | Compositions and methods for treating or preventing diseases of the body passages |
TW513409B (en) | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
DE19630035A1 (en) | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol multiple unit formulations |
AUPO274596A0 (en) | 1996-10-04 | 1996-10-31 | Armstrong, Stuart Maxwell | Method for the treatment of neurological or neuropsychiatric disorders |
US6310085B1 (en) | 1997-10-03 | 2001-10-30 | Clarencew Pty Ltd. | Method for the treatment of neurological or neuropsychiatric disorders |
IT1289160B1 (en) * | 1997-01-08 | 1998-09-29 | Jagotec Ag | FULLY COATED PHARMACEUTICAL TABLET FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS WHICH PRESENT PROBLEMS OF |
DE19707655A1 (en) | 1997-02-26 | 1998-08-27 | Hoechst Ag | Combination preparation for use in dementia |
CA2216215A1 (en) | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
US6210710B1 (en) * | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
US7008950B1 (en) * | 1997-06-05 | 2006-03-07 | Takeda Chemical Industries, Ltd. | Benzofurans as suppressors of neurodegeneration |
TW446561B (en) * | 1997-06-30 | 2001-07-21 | Dev Center Biotechnology | Improved stabilization of prostaglandin drug |
FR2766708B1 (en) * | 1997-07-30 | 2000-05-05 | Galenix Dev | COMPOSITION CONTAINING HYDROXYPROPYLCELLULOSE, HYDROXYPROPYLMETHYLCELLULOSE AND / OR ETHYLCELLULLOSE AS DISINTEGRANTS, AND PROCESS FOR OBTAINING SAME |
JP3797764B2 (en) * | 1997-10-01 | 2006-07-19 | エーザイ株式会社 | Light stabilizing composition |
US20030092737A1 (en) * | 1997-11-14 | 2003-05-15 | Pierre Maffrand Jean | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type |
US20040028735A1 (en) * | 1997-11-14 | 2004-02-12 | Unchalee Kositprapa | Pharmaceutical formulation |
CO4980891A1 (en) | 1997-11-14 | 2000-11-27 | Sanofi Sa | ASSOCIATION OF ACTIVE PRINCIPLES FOR THE TREATMENT OF SENILE DEMENTIA OF THE AZHEIMER TYPE |
FR2772615B1 (en) | 1997-12-23 | 2002-06-14 | Lipha | MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES |
US6251430B1 (en) * | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
JP3987655B2 (en) | 1998-03-03 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Transdermal preparation or suppository containing an anti-dementia drug |
US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
AU3024399A (en) * | 1998-04-03 | 1999-10-25 | Bm Research A/S | Controlled release composition |
US6262081B1 (en) * | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
UA73092C2 (en) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Tablets with enteric coating and method for their manufacture |
EP1101490B1 (en) | 1998-07-28 | 2005-04-13 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
EP1025858A4 (en) * | 1998-08-28 | 2009-03-11 | Eisai R&D Man Co Ltd | Medicinal compositions with relieved bitterness, etc. |
DE19842753A1 (en) | 1998-09-18 | 2000-03-23 | Bayer Ag | Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose |
US6531152B1 (en) * | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
US6322819B1 (en) | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
WO2000024423A1 (en) * | 1998-10-26 | 2000-05-04 | Tanabe Seiyaku Co., Ltd. | Sustained-release particles |
US6797283B1 (en) * | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
HUP0104778A3 (en) * | 1998-12-24 | 2004-05-28 | Janssen Pharmaceutica Nv | Controlled release galantamine composition |
US6659463B2 (en) | 1999-01-08 | 2003-12-09 | Thomas J. Mackey | Interconnecting miniature toy figurine bases with record tracking system |
DE19901040A1 (en) | 1999-01-14 | 2000-07-20 | Knoll Ag | Controlled release dosage forms containing active ingredients which are readily soluble in water |
EP1027886B1 (en) | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
ES2310164T3 (en) | 1999-02-10 | 2009-01-01 | Pfizer Products Inc. | LIBERATION DEVICE CONTROLLED BY THE MATRIX. |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
ATE313319T1 (en) * | 1999-03-31 | 2006-01-15 | Janssen Pharmaceutica Nv | PREGELATINATED STARCH IN A CONTROLLED RELEASE FORMULATION |
EP1086706B1 (en) | 1999-03-31 | 2003-11-26 | Eisai Co., Ltd. | Stabilized compositions containing nootropic drugs |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
AU781048B2 (en) | 1999-09-02 | 2005-05-05 | Nostrum Pharmaceuticals, Inc. | Controlled release pellet formulation |
GB9923045D0 (en) * | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
US20020107173A1 (en) * | 1999-11-04 | 2002-08-08 | Lawrence Friedhoff | Method of treating amyloid beta precursor disorders |
IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
BR0007360A (en) * | 1999-12-23 | 2001-08-14 | Johnson & Johnson | Controlled release composition |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US20030144255A1 (en) * | 2000-03-06 | 2003-07-31 | Bain Allen I | Compositions for prevention and treatment of dementia |
DE10013029A1 (en) | 2000-03-17 | 2001-09-20 | Roehm Gmbh | Multilayer formulation for controlled drug release in colon, comprising drug-containing core having inner and outer coatings of acrylic copolymers with quaternary ammonium and anionic groups respectively |
IN192159B (en) | 2000-05-15 | 2004-02-28 | Ranbaxy Lab Ltd | |
DE10029201A1 (en) * | 2000-06-19 | 2001-12-20 | Basf Ag | Retarded release oral dosage form, obtained by granulating mixture containing active agent and polyvinyl acetate-polyvinyl pyrrolidone mixture below the melting temperature |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
WO2002024174A2 (en) | 2000-09-22 | 2002-03-28 | Galephar M/F | Sustained release composition containing clarithromycin |
GB0025208D0 (en) * | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
ATE266407T1 (en) | 2000-10-30 | 2004-05-15 | Lupin Ltd | RAPIDLY DISRUPTING MEDICINAL COMPOSITION CONTAINING CEFUROXIM AXETIL WITH DELAYED RELEASE |
CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
SE0004671D0 (en) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
US6287599B1 (en) | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
CA2350195C (en) * | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
AU2002248792B2 (en) | 2001-04-18 | 2006-09-21 | Nostrum Pharmaceuticals Inc. | A novel coating for a sustained release pharmaceutical composition |
US20040022853A1 (en) * | 2001-04-26 | 2004-02-05 | Control Delivery Systems, Inc. | Polymer-based, sustained release drug delivery system |
JP4310605B2 (en) | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | Pharmaceutical composition |
AU2002314968B2 (en) | 2001-06-08 | 2006-12-07 | Endo Pharmaceuticals, Inc. | Controlled release dosage forms using acrylic polymer, and process for making the same |
US6693769B2 (en) * | 2001-06-18 | 2004-02-17 | Hitachi Global Storage Technologies Netherlands B.V. | High data rate write head |
EP1404300B1 (en) * | 2001-06-22 | 2009-09-30 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
JP3474870B2 (en) * | 2001-08-08 | 2003-12-08 | 菱計装株式会社 | Elevator |
JP4848101B2 (en) | 2001-08-17 | 2011-12-28 | 株式会社フジモト・コーポレーション | Sustained release micropellet |
EA200400343A1 (en) * | 2001-08-29 | 2004-08-26 | Рэнбакси Лабораториз Лимитед | COMPOSITION WITH CONTROLLED SURVIVAL OF CLARITROMYCIN OR TINIDAZOL |
WO2003017981A1 (en) * | 2001-08-29 | 2003-03-06 | Ranbaxy Laboratories Limited | Controlled release formulation of clarithromycin or tinidazol |
SI1446119T1 (en) * | 2001-09-18 | 2006-08-31 | Nycomed Danmark Aps | Compositions comprising ipatropium and xylometazoline for treatment of the common cold |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
EP1438028A1 (en) | 2001-09-28 | 2004-07-21 | McNEIL-PPC, INC. | Modified release dosage forms |
US20050191359A1 (en) | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
WO2003028660A2 (en) * | 2001-10-04 | 2003-04-10 | Case Western Reserve University | Drug delivery devices and methods |
US6592901B2 (en) | 2001-10-15 | 2003-07-15 | Hercules Incorporated | Highly compressible ethylcellulose for tableting |
AUPR839001A0 (en) * | 2001-10-19 | 2001-11-15 | Eli Lilly And Company | Dosage form, device and methods of treatment |
WO2003039530A1 (en) | 2001-11-07 | 2003-05-15 | Synthon B.V. | Tamsulosin tablets |
US20050163846A1 (en) | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
CN101982199A (en) | 2001-11-21 | 2011-03-02 | 卫材R&D管理有限公司 | Compositions containing acid-unstable physiologically active compounds and process for producing the same |
WO2003053402A1 (en) * | 2001-12-20 | 2003-07-03 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
KR100540035B1 (en) | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | Multi-stage oral drug controlled-release system |
EP1481689A4 (en) * | 2002-02-07 | 2005-10-05 | Eisai Co Ltd | Hair growth stimulants, percutaneous preparations and method of stimulating hair growth |
HRP20020124A2 (en) * | 2002-02-11 | 2003-10-31 | Pliva D D | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
JP4355925B2 (en) * | 2002-02-21 | 2009-11-04 | 大塚製薬株式会社 | Sustained release formulation and method for producing the same |
DE10208344A1 (en) | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Melt extrusion of active ingredient salts |
GB0204772D0 (en) * | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Pharmaceutical dosage forms |
ITMI20020515A1 (en) | 2002-03-12 | 2003-09-12 | Jagotec Ag | SYSTEM FOR THE CONTROLLED RELEASE OF ONE OR MORE ACTIVE INGREDIENTS |
JP5105684B2 (en) | 2002-03-15 | 2012-12-26 | 大塚製薬株式会社 | Sustained pharmaceutical formulation |
FR2838647B1 (en) | 2002-04-23 | 2006-02-17 | PROLONGED RELEASE PARTICLES, PROCESS FOR THEIR PREPARATION AND TABLETS CONTAINING SAME | |
WO2003090723A1 (en) * | 2002-04-23 | 2003-11-06 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
WO2003096874A2 (en) | 2002-05-15 | 2003-11-27 | Sun Pharmaceutical Industries Limited | Coated sustained release tablets of a hygroscopic compound for once-a-day therapy |
DE10224170A1 (en) | 2002-05-31 | 2003-12-11 | Desitin Arzneimittel Gmbh | Retarded release pharmaceutical composition, obtained without use of organic solvents or water by densifying mixture of active agent and retarding polymer in heated rollers |
US20050158380A1 (en) | 2002-06-07 | 2005-07-21 | Manish Chawla | Sustained release oral dosage forms of gabapentin |
SI21223A (en) | 2002-06-19 | 2003-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical composition with stabilised amorphous donepezil,chloride |
IL150509A (en) * | 2002-07-01 | 2007-07-04 | Joseph Kaspi | Pharmaceutical compositions containing donepezil hydrocholoride |
US20060002997A1 (en) | 2002-08-23 | 2006-01-05 | Puneet Shamar | Nitrofurantoin controlled release dosage form |
US20040052844A1 (en) * | 2002-09-16 | 2004-03-18 | Fang-Hsiung Hsiao | Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins |
US20050048119A1 (en) * | 2002-09-20 | 2005-03-03 | Avinash Nangia | Controlled release composition with semi-permeable membrane and poloxamer flux enhancer |
EP1556019A2 (en) * | 2002-10-24 | 2005-07-27 | Merz Pharma GmbH & Co. KGaA | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
DE60318237T2 (en) | 2002-10-24 | 2008-12-18 | Immupharm A/S | PHARMACEUTICAL COMPOSITIONS CONTAINING FLAVONOIDS AND MENTHOL |
US20040162263A1 (en) | 2002-10-31 | 2004-08-19 | Supergen, Inc., A Delaware Corporation | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
AU2003299819A1 (en) * | 2002-12-23 | 2004-07-22 | Human Genome Sciences, Inc. | Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof |
US7910128B2 (en) | 2003-01-03 | 2011-03-22 | Supernus Pharmaceuticals, Inc. | Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics |
WO2004066983A2 (en) | 2003-01-24 | 2004-08-12 | Control Delivery Systems, Inc. | Controlled release of highly soluble agents |
US20040258752A1 (en) | 2003-01-31 | 2004-12-23 | Paruthi Manoj Kumar | Taste masking pharmaceutical composition and process for its preparation |
US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
US7439365B2 (en) * | 2003-11-17 | 2008-10-21 | Usv, Ltd. | Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil) |
AR043467A1 (en) | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | DRUG COMBINATION FOR MOTOR DYSFUNCTION IN PARKINSON'S DISEASE |
JP4933033B2 (en) * | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | Controlled release composition |
EP1607088B1 (en) * | 2003-03-17 | 2019-02-27 | Takeda Pharmaceutical Company Limited | Controlled release composition |
US20060210633A1 (en) | 2003-04-03 | 2006-09-21 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
CA2520321A1 (en) | 2003-04-04 | 2004-10-14 | Pharmacia Corporation | Oral extended release compressed tablets of multiparticulates |
US20040208928A1 (en) | 2003-04-15 | 2004-10-21 | Animal Technology Institute Taiwan | Method for preparing an orally administrable formulation for controlled release |
US20040265375A1 (en) | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
US20040208932A1 (en) | 2003-04-17 | 2004-10-21 | Ramachandran Thembalath | Stabilized paroxetine hydrochloride formulation |
JP2004339162A (en) | 2003-05-16 | 2004-12-02 | Shin Etsu Chem Co Ltd | Pharmaceutical solid preparation containing sparingly soluble medicine and method for producing the same |
WO2004103342A2 (en) | 2003-05-16 | 2004-12-02 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
CA2529746C (en) * | 2003-06-16 | 2010-08-03 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
BRPI0411451A (en) | 2003-06-16 | 2006-07-18 | Allergan Inc | oral dosage forms of memantine |
RU2375048C2 (en) * | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Pharmacological composition with swelling coating |
US20050013863A1 (en) * | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
US20050025829A1 (en) * | 2003-07-29 | 2005-02-03 | Kim Cherng-Ju | Controlled drug release tablets |
CA2534920A1 (en) * | 2003-08-06 | 2005-02-24 | Alza Corporation | Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
EP1658048A2 (en) * | 2003-08-22 | 2006-05-24 | ALZA Corporation | Stepwise delivery of topiramate over prolonged period of time |
US8389008B2 (en) * | 2003-09-19 | 2013-03-05 | Penwest Pharmaceuticals Co. | Delayed release dosage forms |
ATE504288T1 (en) * | 2003-09-26 | 2011-04-15 | Alza Corp | OROS PUSH STICK FOR THE CONTROLLED DELIVERY OF ACTIVE INGREDIENTS |
EP1523979A1 (en) * | 2003-10-13 | 2005-04-20 | Wyeth | Extended release pharmaceutical dosage form |
US20050084531A1 (en) * | 2003-10-16 | 2005-04-21 | Jatin Desai | Tablet with aqueous-based sustained release coating |
US20050129751A1 (en) * | 2003-12-16 | 2005-06-16 | Rothenberg Barry E. | Drug delivery compositions and methods |
US20050129759A1 (en) * | 2003-12-16 | 2005-06-16 | Milan Sojka | Sustained release compositions and controlled delivery method |
US20050169992A1 (en) | 2003-12-23 | 2005-08-04 | Frank Jao | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
US20050175696A1 (en) | 2003-12-29 | 2005-08-11 | David Edgren | Drug granule coatings that impart smear resistance during mechanical compression |
CA2552221A1 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
EP1763337A2 (en) * | 2003-12-31 | 2007-03-21 | Actavis Group HF | Immediate, controlled and sustained release formulations of galanthamine |
US20050163843A1 (en) | 2003-12-31 | 2005-07-28 | Garth Boehm | Alprazolam formulations |
JP2007519724A (en) | 2004-01-26 | 2007-07-19 | シヴィダ・インコーポレイテッド | Controlled and sustained delivery of therapeutic agents based on nucleic acids |
US7670624B2 (en) | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
US20050181044A1 (en) | 2004-02-18 | 2005-08-18 | Jaime Romero | Compositions and methods for timed release of water-soluble nutritional supplements, green coffee extract |
US20050181047A1 (en) | 2004-02-18 | 2005-08-18 | Jaime Romero | Compositions and methods for timed release of water-soluble nutritional supplements |
US20050186275A1 (en) | 2004-02-23 | 2005-08-25 | Standard Chem. & Pharm. Co. Ltd. | Sustained release tamsulosin formulations |
TW200534879A (en) | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
NZ549838A (en) | 2004-03-26 | 2010-04-30 | Eisai R&D Man Co Ltd | Coated controlled-release preparation containing a gastric acid secretion inhibitor |
US20050220875A1 (en) | 2004-03-31 | 2005-10-06 | Agency For Science, Technology And Research | Sustained-release tablet formulation |
US20050220877A1 (en) | 2004-03-31 | 2005-10-06 | Patel Ashish A | Bilayer tablet comprising an antihistamine and a decongestant |
US8535716B2 (en) | 2004-04-01 | 2013-09-17 | Tsrl, Inc. | Methods and composition of extended delivery of water insoluble drugs |
US20050226929A1 (en) | 2004-04-12 | 2005-10-13 | Jianbo Xie | Controlled release opioid analgesic formulation |
US8058291B2 (en) | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
WO2006063025A1 (en) * | 2004-12-07 | 2006-06-15 | Nektar Therapeutics | Stable non-crystalline formulation comprising donepezil |
US20060246003A1 (en) | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20060280789A1 (en) | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
US20090208579A1 (en) | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
MX2007007836A (en) | 2004-12-27 | 2007-08-20 | Eisai R&D Man Co Ltd | Method for stabilizing anti-dementia drug. |
US20090023778A1 (en) | 2005-04-28 | 2009-01-22 | Eisai R&D Management Co., Ltd. | Composition Containing Anti-Dementia Drug |
CN1709229A (en) | 2005-06-10 | 2005-12-21 | 北京阜康仁生物制药科技有限公司 | Memantine hydrochloride orally disintegrating tablet and its preparing method |
-
2005
- 2005-12-27 MX MX2007007836A patent/MX2007007836A/en active IP Right Grant
- 2005-12-27 US US11/793,722 patent/US8481565B2/en active Active
- 2005-12-27 BR BRPI0518396-0A patent/BRPI0518396A2/en not_active Application Discontinuation
- 2005-12-27 JP JP2007529288A patent/JP2008525313A/en not_active Withdrawn
- 2005-12-27 NZ NZ555693A patent/NZ555693A/en not_active IP Right Cessation
- 2005-12-27 CA CA2592605A patent/CA2592605C/en not_active Expired - Fee Related
- 2005-12-27 WO PCT/JP2005/024254 patent/WO2006070930A1/en active Application Filing
- 2005-12-27 EP EP05824466.6A patent/EP1830886B1/en active Active
- 2005-12-27 KR KR1020077014535A patent/KR100866720B1/en active IP Right Grant
- 2005-12-27 RU RU2007128767/15A patent/RU2401125C2/en not_active IP Right Cessation
- 2005-12-27 AU AU2005320547A patent/AU2005320547B2/en not_active Ceased
-
2007
- 2007-06-04 IL IL183650A patent/IL183650A/en not_active IP Right Cessation
- 2007-07-05 NO NO20073482A patent/NO20073482L/en not_active Application Discontinuation
-
2008
- 2008-02-05 HK HK08101338.1A patent/HK1112399A1/en unknown
-
2010
- 2010-02-25 US US12/712,959 patent/US8507527B2/en active Active
-
2012
- 2012-04-24 JP JP2012098985A patent/JP5514249B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU2401125C2 (en) | 2010-10-10 |
NZ555693A (en) | 2010-10-29 |
WO2006070930A1 (en) | 2006-07-06 |
KR20070086667A (en) | 2007-08-27 |
KR100866720B1 (en) | 2008-11-05 |
BRPI0518396A2 (en) | 2008-11-18 |
EP1830886B1 (en) | 2016-04-13 |
IL183650A0 (en) | 2007-09-20 |
NO20073482L (en) | 2007-09-27 |
RU2007128767A (en) | 2009-02-10 |
EP1830886A1 (en) | 2007-09-12 |
US8481565B2 (en) | 2013-07-09 |
MX2007007836A (en) | 2007-08-20 |
US20100152164A1 (en) | 2010-06-17 |
JP5514249B2 (en) | 2014-06-04 |
JP2008525313A (en) | 2008-07-17 |
IL183650A (en) | 2013-12-31 |
AU2005320547A1 (en) | 2006-07-06 |
AU2005320547B2 (en) | 2009-02-05 |
US20080213368A1 (en) | 2008-09-04 |
JP2012144568A (en) | 2012-08-02 |
CA2592605C (en) | 2010-12-07 |
HK1112399A1 (en) | 2008-09-05 |
US8507527B2 (en) | 2013-08-13 |
EP1830886A4 (en) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2592605A1 (en) | Method for stabilizing anti-dementia drug | |
CA2478558C (en) | Naltrexone hydrochloride compositions | |
KR101708538B1 (en) | Methods for treating cardiovascular disorders | |
AU2008304033B2 (en) | Pharmaceutical composition containing esomeprazole | |
US9011912B2 (en) | Extended-release oral dosage forms for poorly soluble amine drugs | |
KR20120064141A (en) | Coated tablet formulation and method | |
JP5208209B2 (en) | Donepezil-containing patch preparation and its package | |
CN102743330A (en) | Pharmaceutical composition | |
JP2014517843A (en) | Compressed core for pharmaceutical composition | |
PL205109B1 (en) | Multiparticulate modified release composition | |
US20120107400A1 (en) | Sustained release composition of theraputic agent | |
CA2275604A1 (en) | Sustained release cisapride mini-tablet formulation | |
EP2172200A1 (en) | Coated preparation | |
KR102408645B1 (en) | Improved stability double-coated tablet Composition including S-omeprazole and manufacturing method thereof | |
WO2015145462A1 (en) | Pharmaceutical compositions of dabigatran | |
WO2005027880A1 (en) | Enteric soft gelatin capsule containing esomeprazole and method of preparation | |
CA2474246A1 (en) | Alkylammonium salts of omeprazole and esomeprazole | |
JP2003500348A (en) | Multiparticulate controlled release selective serotonin reuptake inhibitor formulation | |
AU776384B2 (en) | Stable galenic preparations comprising a benzimidazol and method for the production thereof | |
WO2016102705A1 (en) | Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof | |
KR20220104705A (en) | Tetrabenazine Transdermal Delivery Device | |
KR100983655B1 (en) | Oral Formulations of Benzimidazole Derivatives | |
KR20210137161A (en) | Improved API stability of softgels | |
CN111789808A (en) | Oral pharmaceutical composition and structure thereof | |
NZ621666B2 (en) | Methods for treating cardiovascular disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20191227 |